• <td id="mmqmm"><noscript id="mmqmm"></noscript></td><option id="mmqmm"><noscript id="mmqmm"></noscript></option>
  • <table id="mmqmm"><table id="mmqmm"></table></table><table id="mmqmm"></table>
  • <table id="mmqmm"></table>
  •  

    News


    News detail

    First-in-Class Factor B Inhibitor LNP023
    Source: | Author:EnzymeWorks | Published time: 2021-01-21 | 803 Views | Share:
     LNP023 is a first-in-class, potent and highly selective factor B inhibitor of the alternative complement pathway, and positive results from Phase II studies recently announced by Novartis. A novel chemoenzymatic process was developed by applying an enzyme from EnzymeWorks: https://newdrugapprovals.org/2020/03/11/lnp-023/
     
    ISO 9001:2008 certified

    久久久久久久汣爰,俄罗斯第一次破女第八集,5c5c5c精品视频在线观看
  • <td id="mmqmm"><noscript id="mmqmm"></noscript></td><option id="mmqmm"><noscript id="mmqmm"></noscript></option>
  • <table id="mmqmm"><table id="mmqmm"></table></table><table id="mmqmm"></table>
  • <table id="mmqmm"></table>